Ahmar U. Zaidi/LinkedIn
Jun 14, 2026, 18:01
Ahmar U. Zaidi: The First Pivotal Study of a New Mechanism in Sickle Cell Disease
Ahmar U. Zaidi, Senior Medical Director of Clinical Development at Agios Pharmaceuticals, shared a post on LinkedIn:
“EHA plenary for the RISE UP study!
An incredible moment.
Not because the RISE UP study was on one of the biggest stages in hematology, but because of what it represented.
The first pivotal study of a new mechanism in Sickle Cell disease. The chance to help tell the story of a potential new treatment paradigm in sickle cell disease: PK activation.
There is immense gratitude for the patients, families, investigators, advocates, and colleagues who made this moment possible.
Progress in sickle cell disease belongs to all of them.
I am simply fortunate to be here while their story is told.”
Stay updated with Hemostasis Today.
-
Jun 14, 2026, 18:00Lennart Lenk: Witnessing Former Boss Deliver a Plenary Talk at EHA 2026
-
Jun 14, 2026, 18:00Priya Sriskandarajah: Great Presentations on Recent Advances in Myelofibrosis at EHA 2026
-
Jun 14, 2026, 18:00Tania Lifanova: Another Year of Building Relationships at EHA
-
Jun 14, 2026, 17:59Pratap Kumar: Blood Shortages Are a Health Systems Challenge, Not Just a Donor Shortage
-
Jun 14, 2026, 17:59John Ohd: 3 Great Reasons to Join us Here at EHA 2026
-
Jun 14, 2026, 16:16Andreas Kronbichler: The Intronic Splice-Site Variants in Complement-Mediated Thrombotic Microangiopathy
-
Jun 14, 2026, 16:02Tedros Adhanom Ghebreyesus: WHO and ENHYPEN Celebrating World Blood Donor Day
-
Jun 14, 2026, 16:00Aishee Pal Sadhu: One of the Simplest Ways to Save a Life Is to Donate Blood
-
Jun 14, 2026, 15:51Zoe Billinghurst: Strengthening the Global Rare Blood Disorders Community at EHA 2026